Lifevantage Corporation · NASDAQ:LFVN
Lifevantage — Investor Presentation (September 2026)
47 slides from Lifevantage's investor presentation, September 2026
Slide 1: Mission
MISSION: W E O F F E R P E O P LE A R O U ND T H E W O R LD A B E T T E R P A T H T O W E LLN E S S A N D A H E A LT H Y V I B R A N T LI F E .
Slide 2: Forward Looking Statements
Forward Looking Statements SAFE HARBOR STATEMENT This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects
Slide 3: LifeVantage Fact Sheet
LifeVantage Fact Sheet NASDAQ Ticker LFVN Share price1 $6.36 Shares outstanding1 12.5 million Float1 10.1 million Market Capitalization1 $79.7 million Enterprise Value1 $64.8 million Average Daily Volume1 60,148 Fiscal 2025 Revenue $182.6 million Cash at June 30, 2026 $14.9 million Fiscal 2026 Adjus
Slide 4: LifeVantage At a Glance
LifeVantage At a Glance • Pioneer in Activation and nutrigenomics with patented, scientifically validated products that work with your unique biology and help your body make what it needs for health • Direct Sales industry-leader with sales force of independent Consultants and approximately 104,000
Slide 5: The Activation Company
The Activation Company ACTIVATING WELLNESS AROUND THE WORLD THROUGH DIRECT SALES Working in partnership with thousands of Independent Consultants around the world, LifeVantage, the Activation Company, activates many aspects of wellness. We ACTIVATE physical wellness, inside and out, with products th
Slide 6: Optimal Position for Direct Sales Industry
Optimal Position for Direct Sales Industry ADDRESSING THE TWO LARGEST CATEGORIES IN THE LARGEST MARKETS LIFEVANTAGE OPERATES IN 6 OF THE 10 LARGEST DIRECT SELLING MARKETS GLOBALLY INVESTOR PRESENTATION 6 See the Sales by Product Category Report here: https://heyzine.com/flip-book/WFDSASTATS2024#page
Slide 7: Activation Around the Globe
Activation Around the Globe LIFEVANTAGE PERCENTAGE OF SALES BY AREA $167.7 Billion Industry* Europe 22% Americas 3% 37% Europe 78% Africa/ME Asia Pacific USA, Canada, 1% 40% Puerto Rico, Mexico 19% Japan, Taiwan, Hong Kong, Singapore, Thailand, New Zealand, Australia *Source: World Federation of Dir
Slide 8: The Activation Approach - Take It To Make It
T H I S I S A S U B - H E A D IN G The Activation Approach - Take It To Make It As the years go by, the toll of time, the environment, and daily choices add up. Most turn to supplements to fill the voids left by modern life. But the truth is, supplements meet basic needs but often fall short when it
Slide 9: Protandim Nrf2 Antioxidants
TAKE IT Protandim Nrf2 ® MAKE IT Antioxidants Oxidative stress is a key contributor to the signs of aging, and Protandim Nrf2 Synergizer is the only supplement shown to reduce oxidative stress by 40% in just 30 days. Support your body’s own production of powerful antioxidants to fight the signs of a
Slide 10: Healthy Glow Essentials Antioxidants, Collagen
TAKE IT Healthy Glow Essentials MAKE IT Antioxidants, Collagen Life is hard on your body. You need antioxidants to fight stress, stay balanced and recover. You need collagen support because it's crucial and your body stops making enough in your early 20’s. Do nothing and let life and aging process t
Slide 11: MindBody GLP-1 System
TAKE IT MindBody GLP-1 System MAKE IT GLP-1 This innovative, patent-pending System is clinically shown to naturally increase GLP-1 by an average of 200% as it balances hunger hormones—no injections or prescriptions required. Build better habits, achieve your ideal weight, and become a stronger, heal
Slide 12: Transformative, Patent-Pending Results
Transformative, Patent-Pending Results Key findings from U.S. clinical studies on the MindBody GLP-1 SystemTM include: • Over 200% average increase in GLP-1 over 12 weeks‡‡ • Average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds‡,‡‡ • Up to 9% decrease in to
Slide 13: A Natural Approach
A Natural Approach What is GLP-1? GLP-1 (Glucagon-like Peptide – 1) is a hormone produced naturally in the lower GI tract. It regulates appetite and blood sugar levels, while slowing down the rate at which food leaves the stomach. GLP-1 communicates with the brain along the brain-gut axis to promote
Slide 14: Understanding the Weight Loss Market
Understanding the Weight Loss Market GLP-1 MARKET OVERVIEW In recent years, drugs including those classified as semiglutides and tirzepatides, have not only changed the approach to diabetes treatments, but obesity and weight management as well. This broad class of drugs work by mimicking hormones th
Slide 15: LoveBiome P84 Gut Peptides
TAKE IT LoveBiome P84 MAKE IT Gut Peptides Your gut plays an essential role. Often referred to as your second brain, it's in constant communication to ensure your entire body is functioning properly. However, your gut gets hit hard with daily attacks from your environment, diet, lifestyle and aging
Slide 16: Gut Health: A $32B Market Opportunity Transforming Global Wellness
Gut Health: A $32B Market Opportunity Transforming Global Wellness The gut health market represents one of the most exciting frontiers in wellness and preventive care, with strong momentum and long-term growth potential. Global gut health supplement sales are projected to reach $14.4 billion in 2025
Slide 17: Stacks + Subscriptions for Health Synergies
Stacks + Subscriptions for Health Synergies — Inside and Out We offer several product stacks designed for Subscription. Each provides a unique health solution by delivering activation synergies when the products are used together. Consumers save on products and see and feel even more benefits while
Slide 18: Modernized Compensation Plan Attracts Independent Business Owners
Modernized Compensation Plan Attracts Independent Business Owners Our new Evolve Compensation Plan helps Consultants activate financial wellness and evolve possibilities in their lives. They can choose to earn supplemental income solely through Customer sales or also by building a team of Consultant
Slide 19: History & Focus for the Future
HISTORY & FOCUS FOR THE FUTURE 19
Slide 20: Laser-Focused on the Experience
Laser-Focused on the Experience Since the launch of LV360 initiatives in 2023, LifeVantage has been laser- focused on increasing active monthly purchasers - enrolling new business builders and Customers, and retaining them longer - by focusing on six elements of our direct sales business – product,
Slide 21: #1 Product
#1 Product Attract and retain new consumers with exciting products that fit current industry trends, meet a true health need, and are socially shareable. Our Activators are scientifically shown to be nutrigenomically active, and every product is designed with high- quality ingredients proven to prov
Slide 22: #2 Social
#2 Social Inspire a growing, engaged social community that encourages wellness enthusiasts to feel better, fuel their purpose, and celebrate what it means to live activated. LifeVantage shares performance- driven digital content that creates conversations and attracts and delights consumers with the
Slide 23: #3 Compensation
#3 Compensation Modernized Evolve Compensation Plan helps new Consultants earn faster, rewards them for any way they want to work, and gives them the flexibility to earn only on sales to Customers or also through building a team of Consultants. HI G HLI G HTS Fully redesigned Evolve Compensation Pla
Slide 24: #4 Consumer Experience
#4 Consumer Experience Build trust, create positive experiences, and provide compelling motivators for placing repeat orders. HI G HLI G HTS Created LifeVantage® Rewards Circle loyalty program in which Customers can earn credits to use for future orders when they order products on Subscription. Cons
Slide 25: #5 Digital
#5 Digital Create a connected, digital-first culture to enhance customer relationships and support the Consultant experience. HI G HLI G HTS Recently announced partnership with Shopify with better converting, AI-powered website launching 2026. Improved website experience and Shop by Solution functio
Slide 26: #6 Activation Nation Community
#6 Activation Nation Community Grow the community of those positively impacted by LifeVantage through building our Activation Nation and by leaving a legacy of a better world for all. HI G HLI G HTS Increased number of events to 4 times per year – 2 virtual and 2 in-person—to help keep Consultants a
Slide 27: Financial Overview
Financial Overview INVESTOR PRESENTATION
Slide 28: Business Model
Business Model Long-term (as % of revenue) FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 Target Gross Margin 81.5% 79.7% 79.3% 80.4% 77.6% 80.0% Commissions and Incentives 47.1% 44.4% 42.9% 44.7% 42.2% 43.0% SG&A* 30.7% 32.9% 31.3% 29.8% 32.0% 28.0% Operating Margin* 3.7% 2.4% 5.0% 5.8% 3.3% 9.0% Adjusted
Slide 29: Revenues
Revenues Revenue (USD in thousands) $300,000 $250,000 $200,000 $150,000 $100,000 $50,000 $- 2023 2024 2025 2026 INVESTOR PRESENTATION 29
Slide 30: Revenues by Geography
Revenues by Geography Revenue (USD in thousands) $250,000 $24,694 $200,000 $27,496 $25,394 $26,989 $23,034 • Currently selling products in 18 countries $150,000 $24,148 • USA largest market at 74% in FY26 $100,000 $178,442 • Japan next largest at 13% in FY26 $145,679 $135,404 $50,000 $- 2024 2025 20
Slide 31: Strong Balance Sheet
Strong Balance Sheet (USD in thousands) June 30, 2026 June 30, 2025 Cash and Cash Equivalents $ 14,920 $ 20,201 • Debt Free Inventory 16,167 20,669 • $18.1M in working capital at 6/30/26 Total Current Assets 38,297 50,894 • Clean Equity – only one class of common Total Assets $ 62,111 $ 71,958 share
Slide 32: Robust Capital Allocation Priorities
Robust Capital Allocation Priorities CASH FROM OPERATIONS Invest in Growth Return Value to Stockholders • Dividends • Expand Capabilities • Current quarterly dividend $0.05/share • Special dividend of $0.40/share (Sep’23) • New Product Development • Paid $10.1M in dividends since the • LV360 Initiat
Slide 33: Summary
Summary LIFEVANTAGE Well-positioned with on-trend, scientific products in a growing, global sales channel Continuous focus on product innovation, international market expansion, and positive experiences Subscription-based business model with strong cash flow and high incremental margins Modern busin
Slide 34: Management Team
Management Team INVESTOR PRESENTATION
Slide 35: Management Team
Carl Alissa Kristen Aure Neufeld Cunningham CHIEF FINANCIAL OFFICER | 1 0 . 2 6 . 2 0 2 1 GENERAL COUNSEL | 0 3 . 3 1 . 2 0 2 1 CHIEF SALES OFFICER | 0 6 . 0 6 .2 0 2 2 Certified Public Accountant with more than 24 years of Joined as Vice President of Field Development and named CSO in finance and a
Slide 36: Board of Directors
Board of Directors INVESTOR PRESENTATION
Slide 37: Board of Directors
Raymond Michael Dayton Greer Beindorff Judd CHAIRMAN OF THE BOARD | S I N C E 2 0 1 7 BOARD MEMBER | SINCE 2012 BOARD MEMBER | S I N C E 2 0 2 4 Expert in international logistics, supply chain, and technology Experienced board advisor with wide-ranging experience across Mr. Judd has served as the CE
Slide 38: LifeVantage Board of Directors
LifeVantage Board of Directors BOARD OVERVIEW INVESTOR PRESENTATION 38 *Director data measured as of September 20, 2024.
Slide 39: Scientific Advisory Board
Scientific Advisory Board INVESTOR PRESENTATION
Slide 40: Scientific Advisory Board
Dr. Brett Brimhall, DC DR. JOSEPH LIU, DC & D R . M AY E N N E AG U I R R E , M D DR. CHERYL BONES, DC D R . M E L O D Y R O D AR TE , D O D R . M AR I A C U TL E R , D C DR. JESSICA BUHLER, DC D R . D O R I AN B O S C H , M D D R . K AT K AD I N , D C DR. JEFF PICCIRILLO, MD The Scientific Advisory
Slide 41: Appendix
Appendix INVESTOR PRESENTATION
Slide 42: Recent Operating Results Comparison
Recent Operating Results Comparison LI FEVANTAG E CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Year over Previous Sequential Sequential Most Recent Quarter Prior Year Period Year Quarter Change Change (In thousands, except per share data) Q4 of Fiscal 2026 Q4 of Fiscal 2025 % Q3 of Fi
Slide 43: Historical Income Statements
Historical Income Statements LI FEVANTAG E CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Fiscal Year ended June 30, (In thousands, except per share data) 2024 2025 2026 Revenue, net $ 200,164 $ 228,530 $ 182,586 Cost of sales 41,440 44,864 40,973 Gross profit 158,724 183,666 141,613 Co
Slide 44: Historical Balance Sheet and Cash Flows
Historical Balance Sheet and Cash Flows LI FEVANTAG E SUMMARIZED BALANCE SHEET AND CASH FLOW METRICS As of June 30, (Unaudited, in thousands, except per share data) 2024 2025 2026 Cash and Cash Equivalents $ 16,886 $ 20,201 $ 14,920 Current Portion of Long-term Debt, net - - - Net Cash (Cash and equ
Slide 45: Non-GAAP Reconciliations
Non-GAAP Reconciliations LI FEVANTAG E Adjusted Net Income (Unaudited, in thousands, except per share data) Fiscal Year ended June 30, 2024 2025 2026 GAAP net income $ 2,937 $ 9,805 $ 5,072 Adjustments: Executive team recruiting and transition expenses 198 562 — Executive and non-recurring severence
Slide 46: Non-GAAP Reconciliations
Non-GAAP Reconciliations LI FEVANTAG E EBITDA and Adjusted EBITDA (Unaudited, in thousands) Fiscal Year ended June 30, 2024 2025 2026 GAAP net income $ 2,937 $ 9,805 $ 5,072 Interest (income) expense (430) (431) (164) Provision for income taxes 1,413 2,438 994 Depreciation and amortization 3,581 3,1
Slide 47: INVESTOR PRESENTATION
Park gou INVESTOR PRESENTATION 47